Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26646919 | 0.88 | CHRM3 (0.33) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26646942 | 0.82 | NTSR1 (0.36) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26975112 | 0.81 | PDE10A (0.43) | PDE10ACNR1CNR2HRH4 | |
| SCHEMBL26795912 | 0.79 | PDE4A (0.42) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26975136 | 0.75 | PDE10A (0.71) | CHRM3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL26975125 | 0.75 | PDE10A (0.38) | PDE10ACNR1CNR2 | |
| SCHEMBL26975124 | 0.73 | PDE10A (0.37) | PDE10ACNR1CNR2 | |
| SCHEMBL26791772 | 0.73 | PDE10A (0.37) | PDE10ACNR1CNR2 | |
| SCHEMBL4432262 | 0.69 | PDE10A (0.41) | PDE10A | |
| SCHEMBL25488838 | 0.64 | CNR2 (0.36) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | CHRM3 4863/4885PDE4A 661/4885PDE4B 758/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | CHRM3 4863/4885PDE4A 661/4885PDE4B 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.